OMAHA, Neb., June 13 /PRNewswire-FirstCall/ -- Transgenomic, Inc. today announced that it has entered into a collaborative research agreement with the Canadian Food Inspection Agency ("CFIA") and Transition Technologies Inc., Transgenomic's distributor in Canada. The project is focused on the development of novel molecular PCR- based assays for the detection of animal materials that have been banned from cattle feed as an additional means to verify the effective enforcement of Canada's feed controls. Following development and performance evaluation, such testing methods could be considered for implementation in feed inspection programs.
Banned ingredients in cattle feed include certain protein-based materials, such as meat and bone meal originating from mammals other than pigs and horses. An effective feed ban diagnostic tool requires the ability to detect certain materials from prohibited species such as cattle, sheep, goats, deer and elk. Current microscopic methods of analysis are time-consuming, labor-intensive, and incapable of identifying the animal species origin of tissue components.
Craig Tuttle, Transgenomic's President and Chief Executive Officer, commented, "We are delighted to be collaborating with the CFIA and to contribute to their research efforts in addressing animal health issues. Our Research and Development team is committed to working closely with them to successfully advance this project." Transition Technologies' President, Dr. Scott McGeorge, adds, "We are looking forward to working with the CFIA laboratory and bringing our own laboratory's considerable expertise in support of this joint project."
About Transgenomic: A decade of discovery 1997 -- 2007
Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Specific offerings include WAVE(R) DHPLC Systems, related consumables and assay kits, cytogenetics automated systems, and Transgenomic Discovery and CLIA Lab Services. Transgenomic Discovery and Lab Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: http://www.transgenomic.com.
Transgenomic Cautionary Statements
Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
Transgenomic, Inc.CONTACT: Debra Schneider, Chief Financial Officer of Transgenomic, Inc.,+1-402-452-5400, fax, +1-402-452-5461, investorrelations@transgenomic.com
Web site: http://www.transgenomic.com/
